A co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives.
Despite increasing efforts and support for anti-malarial drug R&D, globally anti-malarial drug discovery and development remains largely uncoordinated and fragmented . The current window of opportunity for large scale funding of R&D into malaria is likely to narrow in the coming decade due to a contraction in available resources caused by the current economic difficulties and new priorities (e.g. climate change). It is, therefore, essential that stakeholders are given well-articulated action plans and priorities to guide judgments on where resources can be best targeted.
The Coordination, Rationalization, and Integration of anti-MALarial drug Discovery & Development Initiatives (CRIMALDDI) Consortium, funded by the EU Framework Seven Programme, attempted in 2009-2010, through a series of interactive and facilitated workshops, to develop priorities for research to expedite the discovery of new anti-malarials. Ian Boulton was the Project Leader for this initiative, responsible for facilitating the workshops as well as contributing to the development of the conclusions and recommendations.It was hoped that the recommendations will help to guide the priorities of the European anti-malarial research as well as the wider global discovery agenda in the coming decade. This paper, published at the start of the project, outlines the methodology to be used in developing the priorities throughout the project.